Long‐term survival and toxicity in patients with neuroendocrine tumors treated with 177 Lu‐octreotate peptide radionuclide therapy
Author:
Affiliation:
1. Fiona Stanley Hospital, Cancer Centre Murdoch Western Australia Australia
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34191
Reference36 articles.
1. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
2. Phase I-II Study of Radiopeptide177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors
3. NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study
4. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
5. StrosbergJ WolinE ChasenB KulkeM BushnellD.Overall survival progression‐free survival and quality of life updates from the NETTER‐1 study: 177Lu‐Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors. Abstract presented at: 15th Annual ENETS Conference; March 7‐9 2018; Barcelona Spain.
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs);Theranostics;2024
2. Unraveling the Impact of177Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation;Journal of Nuclear Medicine;2023-11-16
3. Mid-PRRT Response Predicts Overall Outcome in Patients with Neuroendocrine Neoplasms;2023-07-28
4. Capecitabine/lutetium-(177Lu)-oxodotreotide/temozolomide;Reactions Weekly;2023-07-01
5. Perspective of molecular imaging and peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors: where do we stand?;Journal of Pancreatology;2023-03-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3